[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroendocrine-tumors-net\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroendocrine-tumors-net":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100638922","a-comparison-of-68gadotatate-and-18fambf3tate-for-the-staging-and-assessment-of-neuroendocrine-malignancies-100638922",false,"NCT07621146","A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies","A Prospective and Head-to-head Comparison of [68Ga] Ga-DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies: NET-COMPARE Study","NET-COMPARE","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients referred for and meeting institutional criteria for a \\[68Ga\\]DOTATATE PET\u002FCT for the investigation of a known or suspected neuroendocrine malignancy (BC Cancer criteria APPENDIX A).\n\nExclusion Criteria:\n\n* Pregnant and breast-feeding patients.\n* Patients unwilling or unable to undergo a second PET\u002FCT.\n* Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET\u002FCT bore (70cm diameter).","ALL","18 Years",{"count":20,"type":21},51,"ESTIMATED","OBSERVATIONAL","Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.",[25,26,27,28],"Neuroendocrine Tumors, NET","Pheochromocytoma\u002FParaganglioma","SSTR-expressing Tumors","Medullary Thyroid Carcinoma","NOT_YET_RECRUITING","2026-05-27",{"date":32,"type":33},"2026-06-02","ACTUAL",{"date":35,"type":21},"2026-09-15",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"British Columbia Cancer Agency","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":58,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100628610","management-of-pancreatic-cystic-lesions-using-artificial-intelligence-based-on-eus-and-multimodal-data-100628610","NCT07463872","Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data","A Multimodal Artificial Intelligence Model for Subtyping Diagnosis and Clinical Management of Pancreatic Cystic Lesions Based on Endoscopic Ultrasound and Clinical Information","Inclusion criteria:\n\n* Patients whose EUS results indicates pancreatic cystic or cystoid lesions;\n* Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN);\n* Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cystic neuroendocrine tumor (cNET).\n\nExclusion criteria:\n\n* Patients whose age is less than 18 years old;\n* Patients who have undergone pancreatic surgery before the EUS examination;\n* Patients who have received chemotherapy and radiotherapy for pancreatic tumors before the EUS examination;\n* Pathological results indicate that pancreatic lesions are metastatic lesions from other sites;\n* Patients whose EUS images or reports are missing;\n* EUS image quality does not meet the requirements for review, such as blurry imaging or containing artifacts, biopsy needles, measuring scales, or other additional annotations that are not part of the original EUS image;\n* Patients whose final diagnosis is unclear.",{"count":50,"type":21},500,"The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions.\n\nThe secondary objective is to evaluate the model's effectiveness in risk stratification and clinical management for patients with PCLs.",[53,54,55,56,57,25],"Pancreatic Cystic Lesion","Mucinous Cystadenoma of Pancreas","Intraductal Papillary Mucinous Neoplasm of Pancreas","Pseudocyst Pancreas","Serous Cystadenoma",[59,60,61,62,63,64,65],"pancreatic cystic lesions","artificial intelligence","endoscopic ultrasound","multimodal","differentiation","risk stratification","clinical management","RECRUITING","2026-03-05",{"date":69,"type":33},"2026-03-11",{"date":71,"type":33},"2025-01-01",{"date":73,"type":21},"2026-06",{"name":75,"class":40},"Huazhong University of Science and Technology",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100490969","68ga-ha-dotatate-petct-in-adults-with-neuroendocrine-tumors-100490969","NCT05673031","68Ga-HA-DOTATATE PET\u002FCT in Adults With Neuroendocrine Tumors","Inclusion Criteria:\n\n1. Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.\n2. Age greater than or equal to 18 years.\n3. Able and willing to follow instructions and comply with the protocol.\n4. Provide written informed consent prior to participation in the study.\n5. Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor\n\nExclusion Criteria:\n\n1. Nursing or pregnant females.\n2. Age less than 18 years.\n3. Surgery in the area of interest within the preceding 2 months.","100 Years",{"count":50,"type":21},"To determine if 68Ga-HA-DOTATATE PET\u002FCT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \\[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET\u002FCT, as available\\]",[87],"Neuroendocrine Tumors (NET)","2023-01-04",{"date":90,"type":33},"2023-01-05",{"date":92,"type":21},"2023-02-01",{"date":94,"type":21},"2027-01-01",{"name":96,"class":40},"Alberta Health services"]